Pomerantz LLP investigates ACADIA Pharmaceuticals over potential securities fraud after trial results disappoint investors.

Pomerantz LLP is investigating ACADIA Pharmaceuticals and some of its executives for possible securities fraud following the company's announcement that its drug remlifanserin narrowly missed the primary endpoint in a Phase 2 clinical trial for Alzheimer’s disease psychosis. The news caused ACADIA's stock to drop significantly over two days, prompting analyst downgrades. The investigation aims to determine if the company misled investors about the trial results, which could affect shareholder value and lead to a class action lawsuit.

ACADIA Pharmaceuticals has a market cap of $3.40 billion and an enterprise value of $2.52 billion as of Oct 28, 2026 06:02 WIB on Pluang. Despite the recent news, the stock price on Pluang is up 2.18% at USD 20.17, with a volume of 1,066,084 shares traded. Investor activity shows a strong buy sentiment with 80% of orders being buys and a typical hold time of 77 days.